RNA Formulation Videos

  1. Advancing mRNA-LNP Delivery And Small-Scale Manufacturing, APAC Session 4/22/2026

    Learn how ionizable LNP formulations and scalable, small-scale manufacturing strategies can overcome delivery and production challenges and accelerate the clinical translation of personalized cancer vaccines.

  2. How To Bring Your LNP Formulation To Clinical/Commercial Manufacturing

    Gain valuable insights into key considerations when selecting lipid excipients for LNP formulations and the process development steps necessary to advance them to GMP manufacturing and clinical trials.

  3. RNA Vaccine Development To Phase I 4/14/2022

    Dr. John Lewis, Founder and CEO, Entos Pharmaceuticals, presents RNA Vaccine Development to Phase I.

  4. Addressing Industry Challenges In mRNA Product Commercialization

    While the speed of production and flexibility of mRNA are appealing, several industry challenges must still be addressed to realize the full potential and further expand its use.

  5. Flexible Liquid Nanoparticle (LNP) Systems 12/6/2024

    From research and clinical studies to full-scale production, revolutionize your lipid nanoparticle (LNP) production with flexible and scalable solutions.

  6. Strategies For Scaling Up mRNA Manufacturing 4/11/2022

    The clinical promise of mRNA therapeutics and vaccines is clear, but compared to monoclonal antibodies or viral vectors, their novelty also brings new challenges to the manufacturing process.

  7. Modular Liquid Nanoparticle (LNP) Systems 12/6/2024

    Optimize your lipid nanoparticle (LNP) production with KNAUER's modular systems. Maximize flexibility, scalability, and control to meet the needs of your project.

  8. Advancements In LNP CMC: What Are The Current "Known Knowns"? 12/4/2024

    In this Advancing RNA Live clip, Sanofi’s Sumit Luthra highlights the learnings we’ve made to-date about how our processes — both in terms of unit operations and process conditions — inform our LNP composition/heterogeneity.

  9. Novel Lipid Chemistries And Their Impact On Passive LNP Delivery 2/24/2026

    In this Advancing RNA Live clip, NanoVation’s Dominik Witzigmann and Stealth Co’s John Zuris break down the scientific advancements we’re seeing for each of an LNP’s components (i.e., the ionizable lipid, helper lipid, and PEG), albeit with the caveat that, with these advancements, Freedom to Operate (FTO) continues to grow increasingly complicated.

  10. The Scientific Underpinnings Of mRNA/LNPs 11/28/2022

    In this video, Russell Johnson, VP Formulation Research for RVAC Medicines, and Aalok Shah, Director of Formulation & Drug Delivery, Strand Therapeutics, share their thoughts on the scientific-research and CMC-related reasons that have made the lipid nanoparticle the “darling” of the delivery world for mRNA/RNA products today.